Last updated on August 2019

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

Brief description of study

To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).

Detailed Study Description

This is a randomized, multicenter, double-blind, parallel-group, active-control study. Approximately 280 patients aged 18 years will be enrolled in the study globally. The investigational drug (sparsentan) is a dual acting angiotensin receptor blocker and endothelin receptor antagonist. The active control is irbesartan.

The purpose of the study is to evaluate the potential benefit of sparsentan on kidney function by analyzing change in proteinuria (protein in urine) and estimated glomerular filtration rate (eGFR) as compared to current standard treatment.

Patients enrolled in the PROTECT study (Protocol 021IGAN17001) will be those at high risk of progressing to renal failure. They will be randomly assigned n a 1:1 ratio to either sparsentan or irbesartan, as the active control (current standard treatment) at the Day 1 (Randomization) visit. Study medication (sparsentan and irbesartan) will be administered as a single oral morning dose.

The primary analysis is change in proteinuria (urine protein/creatinine ratio) from baseline at Week 36 in sparsentan-treated patients as compared to irbesartan-treated patients.

Clinical Study Identifier: NCT03762850

Find a site near you

Start Over

Retrophin Investigational Site

Concord, Australia
  Connect »

Retrophin Investigational Site

St Leonards, Australia
  Connect »

Retrophin Investigational Site

Randwick, Australia
  Connect »